Agios director awarded options and RSUs

AGIOS PHARMACEUTICALS director Jacqualyn A. Fouse reported equity compensation and a routine vesting event.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS director Jacqualyn A. Fouse reported equity compensation and a routine vesting event. On June 18, 2026, 2,816 restricted stock units vested and were converted into 2,816 shares of common stock, bringing her direct common stock holdings to 154,156 shares.

On the same date, she received new awards of 14,950 stock options with a strike price of $34.16 per share, expiring on June 18, 2036, and 2,927 new restricted stock units. These 2026 option and RSU grants are scheduled to vest in full on June 18, 2027. The filing shows only acquisitions, with no reported share sales.

Insider Trade Summary

2,816 shares exercised/converted

Exercise 4 txns

Insider FOUSE JACQUALYN A

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted stock units	2,816	$0.00	$0.00
Grant/Award	Restricted stock units	2,927	$0.00	$0.00
Grant/Award	Stock options (right to buy)	14,950	$0.00	$0.00
Exercise	Common stock	2,816	$0.00	$0.00

Holdings After Transaction: Restricted stock units — 2,927 contracts (Direct); Stock options (right to buy) — 14,950 contracts (Direct); Common stock — 154,156 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Key Figures

RSUs vested: 2,816 units/shares Common shares held: 154,156 shares New stock options granted: 14,950 options +3 more

6 metrics

RSUs vested 2,816 units/shares Restricted stock units vesting on June 18, 2026

Common shares held 154,156 shares Direct holdings after June 18, 2026 transactions

New stock options granted 14,950 options Granted June 18, 2026, vesting June 18, 2027

Option strike price $34.16 per share Exercise price for 14,950 options granted June 18, 2026

Option expiration June 18, 2036 Expiration date for 14,950 stock options

New RSUs granted 2,927 units Restricted stock units granted June 18, 2026, vesting June 18, 2027

Key Terms

restricted stock units, stock options, Exercise or conversion of derivative security, Grant, award, or other acquisition

4 terms

restricted stock units financial

"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options financial

"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions did AGIO director Jacqualyn Fouse report on June 18, 2026?

Jacqualyn Fouse reported equity awards and a vesting event on June 18, 2026. 2,816 restricted stock units vested into common shares, and she received 14,950 stock options plus 2,927 new restricted stock units as part of her director compensation.

How many Agios (AGIO) shares does Jacqualyn Fouse hold after these Form 4 transactions?

After the June 18, 2026 transactions, Jacqualyn Fouse directly holds 154,156 shares of Agios common stock. This reflects the delivery of 2,816 shares from vested restricted stock units added to her prior holdings, with no reported sales in this filing.

What are the terms of the new stock options Agios (AGIO) granted to Jacqualyn Fouse?

Agios granted Jacqualyn Fouse 14,950 stock options on June 18, 2026 at a strike price of $34.16 per share. According to the filing, these options vest 100% on June 18, 2027 and expire on June 18, 2036, if not exercised earlier.

What are the vesting schedules for Jacqualyn Fouse’s Agios restricted stock units?

Restricted stock units granted to Jacqualyn Fouse on June 18, 2025 vested in full on June 18, 2026, delivering 2,816 shares. New restricted stock units granted on June 18, 2026 will vest in full on June 18, 2027, with one share delivered for each vested unit.

Did Jacqualyn Fouse sell any Agios (AGIO) shares in this Form 4?

The Form 4 reports only acquisitions and vesting-related conversions, with no sales indicated. Shares from 2,816 vested restricted stock units were delivered as common stock, and she received new stock option and restricted stock unit grants as director compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 05:22 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOUSE JACQUALYN A

(Last)

(First)

(Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	06/18/2026		M		2,816	A	$0	154,156	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted stock units	⁽¹⁾	06/18/2026		M			2,816	⁽²⁾	⁽²⁾	Common stock	2,816	$0	0	D
Restricted stock units	⁽¹⁾	06/18/2026		A		2,927		⁽³⁾	⁽³⁾	Common stock	2,927	$0	2,927	D
Stock options (right to buy)	$34.16	06/18/2026		A		14,950		⁽⁴⁾	06/18/2036	Common stock	14,950	$0	14,950	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Remarks:

	/s/ William Cook, as Attorney-in-fact for Jacqualyn Fouse	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR